Literature DB >> 19842898

The effects of cyclooxygenase (COX)-2 inhibition on ischemia-reperfusion injury in liver transplantation.

Kiyohiro Oshima1, Yoshihiro Yabata, Daisuke Yoshinari, Izumi Takeyoshi.   

Abstract

PURPOSE: Our objective was to evaluate whether COX-2 inhibition with FK3311, a selective cyclooxygenase (COX)-2 inhibitor, improves transplanted liver function.
METHODS: Inbred male Lewis rats weighing 200-260 g were used. The donor liver was perfused with cold University of Wisconsin (UW) solution and then stored in the same solution at 4 degrees C for 18 hr. After the preservation period, orthotopic liver transplantation was performed. Animals were divided into three groups: the control group; the FK low-dose group (1 mg/kg FK3311 i.v. 20 min before reperfusion); and the FK high-dose group (3 mg/kg FK3311 i.v. 20 min before reperfusion). Survival rate, serum GOT and GPT levels, liver tissue blood flow, and serum thromboxane B(2) (TxB(2)) levels were compared among groups.
RESULTS: Survival rate was significantly better (p <. 05) and serum GOT levels 30 min after reperfusion were significantly lower (p <. 05) in the FK high-dose group compared to the other two groups. Four hours after reperfusion, GPT levels and liver tissue flow were significantly (p <. 05) better in the FK high-dose group compared to the control. Both 30 min and 4 hr after reperfusion, serum TxB(2) levels were significantly lower in the FK high-dose group compared to the control (p <. 05).
CONCLUSION: COX-2 activity results in deteriorated liver function after I/R injury associated with transplantation, and selective COX-2 inhibition improved liver graft function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19842898     DOI: 10.1080/08941930903040080

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  6 in total

1.  Comprehensive and innovative techniques for liver transplantation in rats: a surgical guide.

Authors:  Tomohide Hori; Justin H Nguyen; Xiangdong Zhao; Yasuhiro Ogura; Toshiyuki Hata; Shintaro Yagi; Feng Chen; Ann-Marie T Baine; Norifumi Ohashi; Christopher B Eckman; Aimee R Herdt; Hiroto Egawa; Yasutsugu Takada; Fumitaka Oike; Seisuke Sakamoto; Mureo Kasahara; Kohei Ogawa; Koichiro Hata; Taku Iida; Yukihide Yonekawa; Lena Sibulesky; Kagemasa Kuribayashi; Takuma Kato; Kanako Saito; Linan Wang; Mie Torii; Naruhiko Sahara; Naoko Kamo; Tomoko Sahara; Motohiko Yasutomi; Shinji Uemoto
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

2.  The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart.

Authors:  Nevena Barudzic; Drenka Turjacanin-Pantelic; Vladimir Zivkovic; Dragica Selakovic; Ivan Srejovic; Jovana Joksimovic; Jovana Jakovljevic; Dragan M Djuric; Vladimir Lj Jakovljevic
Journal:  Mol Cell Biochem       Date:  2013-06-09       Impact factor: 3.396

Review 3.  Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury.

Authors:  Heena Khan; Kunal Sharma; Amit Kumar; Amarjot Kaur; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2022-02-17       Impact factor: 4.575

4.  ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury.

Authors:  Naoko Kamo; Bibo Ke; Amir A Ghaffari; Xiu-da Shen; Ronald W Busuttil; Genhong Cheng; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

Review 5.  A systematic review of pharmacological treatment options used to reduce ischemia reperfusion injury in rat liver transplantation.

Authors:  Kenya Yamanaka; Philipp Houben; Helge Bruns; Daniel Schultze; Etsuro Hatano; Peter Schemmer
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

6.  Hepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.

Authors:  Sergio Duarte; Hiroyuki Kato; Naohisa Kuriyama; Kathryn Suko; Tomo-O Ishikawa; Ronald W Busuttil; Harvey R Herschman; Ana J Coito
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.